Quantify

BioNTech SE vs Moderna, Inc. — Stock Comparison

BioNTech SE (BNTX) and Moderna, Inc. (MRNA) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.

BNTX
BioNTech SE
$92.14
▲ 1.33%
vs
MRNA
Moderna, Inc.
$46.88
▼ 0.80%
Q·Score Winner
Moderna, Inc.
MRNA4.9/10vs 4.6/10

Moderna, Inc. narrowly edges BioNTech SE on Q·Score (4.9 vs 4.6 out of 10), led by Growth (8.3 vs 2.1) and Health (9.4 vs 7.7). BioNTech SE scores higher on Valuation, reflecting stronger P/E and price-target positioning. Analyst consensus targets imply greater upside for BNTX (+33.5%) than for MRNA (-7.8%).

Q·Score Breakdown

4.6
Bearish
Overall
4.9
Bearish
1.5
Quality
0.6
7.7
Health
9.4
2.1
Growth
8.3
6.4
Valuation
3
6.8
Sentiment
3.9
BNTX

Clean balance sheet with low leverage (0.0× debt-to-equity).

⚠ currently unprofitable (-45% margin).

MRNA

Clean balance sheet with low leverage (0.2× debt-to-equity).

⚠ currently unprofitable (-144% margin).

Analyst Consensus

Bullish
+33.5%
Target $123.04
19 analysts
Neutral
-7.8%
Target $43.20
20 analysts

Fundamentals

BNTX
MRNA
-17.7×
Forward P/E
-11.2×
-44.64%
Profit Margin
-143.55%
78.65%
Gross Margin
-69.89%
-6.66%
ROE
-36.56%
-35.40%
Revenue Growth
260.20%
1.37
Beta
1.06
$23.3B
Market Cap
$18.6B
52-Week Range
BNTX
$8028% of range$124
MRNA
$2266% of range$60

Frequently Asked Questions

BNTX vs MRNA: which stock scores better overall?

Based on Q·Score, Moderna, Inc. (MRNA) scores 4.9/10 versus BioNTech SE (BNTX) at 4.6/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.

Which has better revenue growth: BNTX or MRNA?

Moderna, Inc. (MRNA) scores higher on Growth (8.3/10 vs 2.1/10). BioNTech SE reports revenue growth (-35.4% YoY) while Moderna, Inc. reports (260.2% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.

Is BNTX or MRNA more attractively valued?

BioNTech SE (BNTX) scores higher on Valuation (6.4/10 vs 3/10). Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.

What do analysts say about BNTX vs MRNA?

There are 19 analysts covering BNTX with a consensus price target of $123.04, and 20 analysts covering MRNA with a consensus target of $43.20. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.

Which is more profitable: BNTX or MRNA?

BioNTech SE (BNTX) scores higher on Quality (1.5/10 vs 0.6/10). Net profit margin: BNTX at -44.6%, MRNA at -143.6%. Quality scores reflect profit margins, return on equity, and free cash flow generation.

Which has stronger financial health: BNTX or MRNA?

Moderna, Inc. (MRNA) scores higher on Financial Health (9.4/10 vs 7.7/10). Market beta: BNTX at 1.37, MRNA at 1.06. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.

What are the market caps of BNTX and MRNA?

BioNTech SE (BNTX) has a market capitalisation of $23.3B, while Moderna, Inc. (MRNA) has a market cap of $18.6B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.

Related Comparisons

MRNA vs PFEAMGN vs MRNAGILD vs MRNA

Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →

Data provided by Yahoo Finance ·  Updated on each page load ·  For informational purposes only · Not financial advice · Quantify.biz © 2026